Crossmark

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Crossref DOI link: https://doi.org/10.1038/s41409-023-02027-y

Published Online: 2023-06-29

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maffini, Enrico https://orcid.org/0000-0001-7356-2328
Ngoya, Maud

Galimard, Jacques-Emmanuel https://orcid.org/0000-0001-9102-4427
Harbi, Samia

Kröger, Nicolaus https://orcid.org/0000-0002-2961-4183
Platzbecker, Uwe

Sengeloev, Henrik

Craddock, Charles https://orcid.org/0000-0001-5041-6678
Potter, Victoria

Choi, Goda

Chevallier, Patrice https://orcid.org/0000-0003-3142-5581
Stölzel, Friedrich

Tholouli, Eleni

Maertens, Johan https://orcid.org/0000-0003-4257-5980
Ciceri, Fabio https://orcid.org/0000-0003-0873-0123
Cornelissen, Jan

Sanz, Jaime https://orcid.org/0000-0001-6934-4619
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Lanza, Francesco https://orcid.org/0000-0002-5189-7167
Nagler, Arnon

Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
License Information

Text and Data Mining valid from 2023-06-29

Version of Record valid from 2023-06-29
More Information

Article History

Received: 9 November 2022

Revised: 4 June 2023

Accepted: 21 June 2023

First Online: 29 June 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below